Physician profile
Chandra Sharma
NPI 1194952614
$469.50
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.49 · 2020: $60.40 · 2021: $127 · 2022: $67.28 · 2023: $103 · 2024: $72.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $88.32 | 2020-2021 | |
| Glaxosmithkline, LLC. | $61.76 | 2023 | Trelegy Ellipta |
| Pfizer INC. | $46.27 | 2019-2021 | |
| Abbvie INC. | $42.37 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $37.61 | 2022 | |
| Biotronik Nro, INC. | $26.30 | 2024 | Prospera |
| Nestle Healthcare Nutrition INC. | $25.95 | 2021 | |
| Eisai INC. | $25.68 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $22.05 | 2023 | Rexulti |
| Hologic Sales and Service, LLC | $21.08 | 2024 | Aptima |
| Astellas Pharma US INC | $19.11 | 2023 | Veozah |
| Novo Nordisk INC | $16.00 | 2021 | |
| Sanofi Pasteur INC. | $13.19 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.54 | 2022 | |
| Amarin Pharma, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.